SAB Biotherapeutics, Inc. (SABSW)
USD 0.04
(-42.86%)
USD 0.04
(-42.86%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -25.11 Million | 3.75 Million | 3.75 Million | 10 Million | -9.21 Million |
| Net Income | -42.19 Million | -17.14 Million | -17.14 Million | 20.11 Million | -8.98 Million |
| Depreciation & Amortization | 3.74 Million | 1.65 Million | 1.65 Million | 548.17 Thousand | 323.4 Thousand |
| Deferred income taxes | -2.85 Million | - | - | -2252.00 | 421.00 |
| Stock-based compensation | 2.42 Million | 2.67 Million | 2.31 Million | 1.29 Million | 371.38 Thousand |
| Change in working capital | 2.32 Million | 13.45 Million | 13.45 Million | -11.95 Million | -923.36 Thousand |
| Other non-cash items | 11.43 Million | 3.47 Million | 3.47 Million | -2.00 | 1.00 |
| Investing Cash Flow | -152.7 Thousand | -10.94 Million | -10.94 Million | -12.72 Million | -608.74 Thousand |
| Investments in PPE | -197.15 Thousand | -10.94 Million | -10.94 Million | -12.73 Million | -608.74 Thousand |
| Acquisitions | 44.45 Thousand | 76.39 Thousand | - | 9000.00 | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -152.7 Thousand | -76.39 Thousand | -10.94 Million | - | - |
| Financing Cash Flow | 66.77 Million | 34.11 Million | 34.11 Million | 8.98 Million | 3.68 Million |
| Debt repayment | -390.44 Thousand | -227.26 Thousand | -227.26 Thousand | -1.57 Million | -623.27 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | -5.52 Million | - | - | - |
| Common Stock Issuance | 67.16 Million | 76.97 Thousand | 6750.00 | 9.9 Million | - |
| Other Financing Activities | 59.4 Million | 39.79 Million | 34.34 Million | 661.61 Thousand | 4.3 Million |
| Accounts receivables | 5.55 Million | 12.55 Million | 12.55 Million | -17.75 Million | -2.56 Million |
| Accounts payables | -2.7 Million | -2.93 Million | -2.93 Million | 5.21 Million | 1.55 Million |
| Inventory | - | - | - | 484.84 Thousand | - |
| Other working capital | -528.63 Thousand | 3.83 Million | 3.83 Million | 100 Thousand | 84.49 Thousand |
| Cash at beginning of period | 15.04 Million | 12.61 Million | 12.61 Million | 6.34 Million | 12.48 Million |
| Cash at end of period | 56.56 Million | 39.54 Million | 39.54 Million | 12.61 Million | 6.34 Million |
| Capital Expenditure | -197.15 Thousand | -10.94 Million | -10.94 Million | -12.73 Million | -608.74 Thousand |
| Effect of forex changes on cash | 18.14 Thousand | - | - | - | - |
| Net cash flow / Change in cash | 41.51 Million | 26.93 Million | 26.93 Million | 6.26 Million | -6.14 Million |
| Free Cash Flow | -25.31 Million | -7.18 Million | -7.18 Million | -2.72 Million | -9.82 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -7.33 Million | -5.02 Million | -22.85 Million | -42.19 Million | -5.1 Million | -6.88 Million |
| Depreciation & Amortization | 1.02 Million | 1.98 Million | 944.4 Thousand | 3.74 Million | 985.44 Thousand | 892.26 Thousand |
| Deferred income taxes | - | - | -2.53 Million | -2.85 Million | - | 357.51 Thousand |
| Stock-based compensation | 601.43 Thousand | 617.44 Thousand | 536.87 Thousand | 2.42 Million | 639.24 Thousand | 644.81 Thousand |
| Change in working capital | 263.33 Thousand | -2.77 Million | -427.4 Thousand | 2.32 Million | -1.49 Million | 37.13 Thousand |
| Other non-cash items | 159.43 Thousand | -1.18 Million | 10.88 Million | 11.43 Million | -195.47 Thousand | 50 Thousand |
| Investing Cash Flow | 11.21 Million | -31.35 Million | -67.86 Thousand | -152.7 Thousand | -40.85 Thousand | -22.68 Thousand |
| Investments in PPE | -52.51 Thousand | -129.07 Thousand | -67.86 Thousand | -197.15 Thousand | -85.3 Thousand | -22.68 Thousand |
| Acquisitions | - | - | -44.45 Thousand | 44.45 Thousand | 44.45 Thousand | - |
| Investment purchases | -105 Thousand | -31.23 Million | - | - | - | - |
| Sales/Maturities of investments | 11.37 Million | - | - | - | - | - |
| Other Investing Activities | 11.37 Million | -129.07 Thousand | -152.7 Thousand | -152.7 Thousand | - | - |
| Financing Cash Flow | -252.32 Thousand | -227.02 Thousand | 67.63 Million | 66.77 Million | -140.3 Thousand | -363.78 Thousand |
| Debt repayment | -252.32 Thousand | -247.43 Thousand | -477.76 Thousand | -390.44 Thousand | -142.73 Thousand | -363.78 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 20.41 Thousand | 67.15 Million | 67.16 Million | 2430.00 | - |
| Other Financing Activities | -68.71 Thousand | -167.39 Thousand | 60.88 Million | 59.4 Million | - | - |
| Accounts receivables | 193.23 Thousand | -193.23 Thousand | - | 5.55 Million | 361.73 Thousand | 401.38 Thousand |
| Accounts payables | -45.03 Thousand | 243.35 Thousand | -105.77 Thousand | -2.7 Million | -320.67 Thousand | -41.11 Thousand |
| Inventory | - | - | 547.14 Thousand | - | -268.41 Thousand | -278.72 Thousand |
| Other working capital | 115.14 Thousand | -2.82 Million | -321.63 Thousand | -528.63 Thousand | -1.26 Million | -44.41 Thousand |
| Cash at beginning of period | 14.03 Million | 56.56 Million | 2.42 Million | 15.04 Million | 7.77 Million | 13.06 Million |
| Cash at end of period | 17.24 Million | 14.03 Million | 56.56 Million | 56.56 Million | 2.42 Million | 7.77 Million |
| Capital Expenditure | -52.51 Thousand | -129.07 Thousand | -67.86 Thousand | -197.15 Thousand | -85.3 Thousand | -22.68 Thousand |
| Effect of forex changes on cash | 28.28 Thousand | -28.27 Thousand | 18.14 Thousand | 18.14 Thousand | - | - |
| Net cash flow / Change in cash | 3.2 Million | -42.53 Million | 54.14 Million | 41.51 Million | -5.34 Million | -5.28 Million |
| Free Cash Flow | -7.83 Million | -11.04 Million | -13.51 Million | -25.31 Million | -5.25 Million | -4.92 Million |
SANCO
9519
U1DA
HCH
002424
RAJRATAN